

# Abstract Submission for CCR-East/Destin 2021

Join our abstract presenters at CCR20 for faculty rounded poster presentations across multiple topic areas. Faculty TBD have agreed to lead the CME approved rounding Thursday afternoon, August 12, 2021.

Accepted abstracts will be published in an abstract program book and be available in the phone app and online! Plus, with reporters onsite, your research could have global impact! Abstracts and other meeting activities from CCR 2020 were covered in numerous articles, creating memorable media impressions.

## General Information

1. Accepted abstracts, which the faculty rounders decide will be presented, will be chosen onsite by rounding faculty and allowed as 3-minute poster presentations. The Program Committee will determine the format, based on the abstract topic and relationship to others submitted. The Program Committee reserves the right to establish other abstract presentation formats and to assign accepted abstracts to these as long as the criteria are met.
2. All abstract presentations and question and answer periods will be in English.
3. Abstracts selected may be published exactly as submitted in the CCR Abstract program book August 11, 2021 version. Full text of the abstracts will be viewable in the CCR Phone App beginning, August 10, 2021, at 8 a.m. Central Time. The CCR Abstract program book will contain the full text of accepted abstracts with title, author, up to two institutions and presentation time information will be available online on August 11, 2021.
4. All accepted abstract presenters must be registered attendees at CCR-D 21 and have a full symposium meeting badge.
5. Submitting authors will be notified via email regarding acceptance disposition.
6. CCR is unable to reimburse any abstract presenters for travel, hotel, or per diem expenses.
7. General Information is subject to change due to circumstances beyond the CCR's control.

## Submission Policies

1. CCR21 abstracts must be SUBMITTED BY 11:59 p.m. CST on Tuesday June 24, 2021. The Congress of Clinical Rheumatology is not responsible for abstracts that are not submitted by this deadline date.
2. "INCOMPLETE" Submissions cannot be processed.
3. The abstract should be "peer reviewed" but abstracts for "late breaking news" may be accepted at the discretion of the CCR staff.
4. Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to register for the meeting by June 24, 2021, may jeopardize inclusion of abstract.
5. There is a limit of two abstract submissions per investigator. The submitting author is considered to be the presenting author unless another coauthor is appointed to present and CCR staff is notified by June 24, 2021 of the change. Any such coauthor must also be registered as a CCR-D 21 full symposium attendee. Cancellation and registration refund of the original author's registration will be according to CCR's registration cancellation refund policies and authors cannot be simply "substituted."

6. Two investigators should not submit the same research; abstracts that appear to be replicate versions of a single study will be rejected. Submissions will be checked for duplication and replicate versions will be rejected.
7. Investigators should submit the abstract to only one category. A submitter must choose the category that best encompasses the abstract subject within the activity. Be sure to review all the abstract submission options before selecting and starting the submission process. Categories may be added, combined or deleted depending upon submissions.
8. Please follow all instructions for completing the submission. For general abstracts, be sure to structure the content into Background, Methods, Results, and Conclusion sections. Other submission types may require a slightly different structure.
9. Clarity of expression will be considered in the review process. The overall quality of language used should assure comprehension by the reader.
10. It is preferable to use a maximum of five unique abbreviations in the body of the abstract. Only the most widely recognized abbreviations should appear in the title. Place abbreviations in parentheses after the full word the first time it appears. Abbreviations increase the difficulty of reading and evaluating abstracts, which will be considered in the review process.
11. If authors' names appear on more than one abstract, their names must appear and be spelled identically on each abstract in order to facilitate proper indexing. **Do not list authors with initials only. If the presenter is not an author, then the presenter's name should appear somewhere on the abstract as the presenter.**
12. After June 24, 2021, the system will be closed, and **complete** abstracts will be forwarded for the reviewing process. An author may not revise or resubmit an abstract in order to make changes or corrections after this deadline; the abstract may be withdrawn or, if accepted, the error may be indicated during the presentation.
13. Adding or removing authors after the submission deadline is not permitted.
14. Proofread abstracts carefully to avoid errors before they are submitted. CCR is not authorized to make changes to a submission. This includes typographical errors. Your abstract, if selected, will be published exactly as submitted. Tables and graphics, if the quality submitted is poor, will also appear badly. All tables and graphics should be included within the word text submission. **Only the word text submission will be included for acceptance.**
15. If you choose to withdraw an abstract after the submission deadline, this request must be received by the CCR in writing and sent to [pmclain@ccrheumatology.com](mailto:pmclain@ccrheumatology.com) prior to June 24, 2021. After this date, withdrawals are accepted but abstracts will still appear in publications.
16. All abstracts and posters **MUST** contain disclosures and a COID form must be completed and accompany the submission. Since the poster session is approved for CME credit, disclosures are absolutely required and **no abstract or poster will be accepted without the disclosures.**

### **Eligibility Policies**

1. Abstracts are eligible for consideration if the paper has been presented at a U.S. national or international meeting held prior to the CCR Annual Scientific Session.

2. No case reports will be accepted except those submitted through NYRIF and approved by NYRIF faculty.
3. Original abstracts may be considered but will need prior approval by CCR staff.
4. Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association.
5. The Program Committee endorses the position of the American Association for the Advancement of Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.

## Disclosure Policies

1. The presenter and lead investigator **MUST** have their disclosure information on all abstracts and posters. A complete COID form **MUST** be submitted with the abstract.
2. Presenting authors and lead investigators will be asked to comply with the ACCME Disclosure Policy. Indication of the relationship and the associated commercial entity is required for all presenting authors and the lead investigators.
3. **The presenting author may be an employee of a pharmaceutical company as long as the presenter's Conflict of Interest in the written abstract, on the poster and on the COID form accurately states any and all relationship(s) of the presenter to the company.** Presenters must also verbally disclose any pertinent conflicts of interest at the beginning of their presentations. *In addition, the presenting author must be someone who has integral information about the integrity of the data, accuracy of the data analysis, and can approve the data for presentation.* The disclosure must contain the main conflicts of interest that the authors would have disclosed.
4. All presenting authors and lead investigators must disclose by **June 24, 2021**.
5. **Failure of lead investigator or other approved presenter to submit a completed COID form and disclosure information on an abstract or poster will result in the removal of an accepted abstract from the program.**
6. COID forms are available for download on the CCR website and should be completed and uploaded with the abstract in the requested location in the registration portal process. All abstracts may **only** be submitted by the presenter during the presenter's registration. Lead investigators with expired or nonexistent disclosure information will automatically be sent email notification and failure to provide accurate disclosure by the deadline will result in non-inclusion in the final print and online versions.
7. Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers and/or research sponsors (including, but not limited to, academic institutions, commercial entities, and non-profit organizations).
8. Traditional flat board poster boards for presentations will be used and **the presentation MUST CONTAIN the disclosure information of the presenting author and lead investigator somewhere on the poster** and presenters will be required to verbally disclose at the beginning of their presentations. **Poster presentations without disclosure information will be removed from a poster board.**

## Abstract Presentation

1. At the time of an abstract submission, the submitter must be the presenting author. To be eligible to present, authors **MUST** confirm that they have full access to all of the data in the study and take responsibility for the integrity of the data, accuracy of the data analysis, and approving the data for presentation.
9. The presenting author need not be the first author and **may be an employee of a pharmaceutical company as long as the presenter's Conflict of Interest in the written abstract, on the poster and on the COID form accurately states any and all relationship(s) of the presenter to the company.** Presenters must also verbally disclose any pertinent conflicts of interest at the beginning of their presentations. *In addition, the presenting author must be someone who has integral information about the integrity of the data, accuracy of the data analysis, and can approve the data for presentation. The disclosure must contain the main conflicts of interest that the authors would have disclosed.*
2. The presenter is required to speak English when presenting, as this is the designated language of the meeting.
3. Only one presenter is permitted per abstract.
4. **Important:** The presenting author is the sole point of contact for all abstract co-authors. CCR will direct all co-author inquiries to the presenting author, who **MUST** be the submitter.

## Permissions and Reprints

The Annual Meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by CCR. The information and materials displayed and presented during this meeting are the property of the CCR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the Congress of Clinical Rheumatology and the presenter. Any use of the program content for commercial purposes (which includes, but is not limited to, oral presentations, audiovisual materials used by speakers, and program handouts) without the written consent of the CCR is prohibited. This policy applies before, during, and after the meeting. The CCR will enforce its intellectual property rights and penalize those who infringe upon them.

## Abstract Submission Instructions

### Entering Abstract Information

#### A. Title

1. Do not italicize, underline, superscript or subscript any items in the title. Do not capitalize all letters in the title.
2. Do **NOT** put CCR guidelines, dates or submission information on your abstract.
3. Do not include authors in the title. If you enter authors in the title, they will be removed.
4. Do not include institutions in the title. If you enter institutions in the title, they will be removed.

5. Capitalize the first letter of all major words in the title as well as articles and conjunctions of four letters or more.
6. It is not necessary to capitalize prepositions or words four letters or less in headings.
7. Do not use abbreviations in the title, unless they are well known and accepted. Common abbreviations may be used in the abstract body.
8. Do not end the title with a period.
9. If the title contains more than one statement, use only one space after a period or colon.
10. Do not use a comma before “and” in a series.
11. Use a comma for number 1,000 and above.
12. Substitute a colon for a dash/hyphen except when using prefixes.
13. Do not use quotation marks in a title.
14. Hyphenate the first prefix word when there is more than one prefix word used such as Non- Anti...

## **B. Institutions and Authors**

1. Authors should be listed below the title. List the complete name including a full first name and initials.
2. Please use English characters when entering names and eliminate any non-English characters such as tildes and umlauts.
3. Do not include title, degrees, or suffix.
4. If more than one abstract is submitted, please spell authors in exactly the same manner. This is important when indexing all authors in the CCR Phone app planner systems.
5. The author order is the order that authors will be listed in publications if the abstract is selected for presentation.
6. The contact information is not used as part of the institutions listed in any abstract publication. Institutions are entered in a separate area.
7. The submitting author will be notified about the outcome of the review and selection process.
8. Anything listed on the abstract may appear “as is” in the CCR Poster syllabus book and on the cell phone app.

## **C. Abstract (Important Issues)**

1. **No case reports will be accepted** except those submitted through NYRIF and approved by NYRIF faculty.
2. Abstracts **MUST** conform to specific size limits or they will remain in an incomplete status and will not be reviewed. Your abstract may not contain more than 2,750 characters, **not including spaces**. Any graphic, table or picture should be included in the body of the word doc and is not included as part of the 2,750-character limit.
3. Use the standard Times New Roman font for text and Symbol font for symbols (**DO NOT USE A THIRD-PARTY SYMBOL FONT!**); any other fonts will not be accepted. Set all text as flush left, unjustified, and wrapping text as you type. Do **NOT** place hard returns at the end of each line.
4. **The abstract must be a word doc. No pdf files will be accepted.**

## **Abstract Body/Text**

1. **No case reports will be accepted** except those submitted through NYRIF and approved by NYRIF faculty.
2. You may upload the body of the abstract directly into the space provided for the abstract body. **All graphics &/or images must be incorporated into the word doc.** Do not upload them separately. Only one word doc may be uploaded per abstract.
3. Please do not use more than five unique abbreviations in the body of the abstract. Spell out the complete phrase followed by the abbreviation in parentheses the first time the abbreviation is used. Abbreviations are not allowed in the title of the abstract, unless well-know, i.e., MTX, TNF.
4. Do not include the title in the abstract body. The title and authors are not included in the character count.
5. Do not include institutions in the abstract body. They may be listed under or with the authors.
6. The abstract must be presented in the following sequence, using the headings listed: **Background:** In an initial paragraph, provide relevant information regarding the background and purpose of the study, preferably in no more than one or two sentences. **Methods:** Briefly state the methods used. **Results:** Summarize the results in sufficient detail to support the conclusions. **Conclusion:** State the conclusions reached. It is not satisfactory to state “the results will be discussed.”
7. Please proofread carefully for factual, spelling, and size errors. If accepted, the abstract will be published exactly as it appears on the online submission system confirmation page.
8. All abstracts and posters **must** contain a disclosure either under the authors or at the end of the abstract.

## ***Clinical Implications***

1. In a couple sentences, state the main clinical implications (or significance) of your study.
2. This information may be used as discussion points in educational activities at CCR 2021.

## ***Tables***

1. You may include an image of a table, but it **MUST** be inserted in the abstract’s word doc body.
2. A table equals 600 characters but it will **not be included** as part of the 2,750-character limit if inserted into the word doc.

## ***Graphics***

1. Graphics should be high resolution and **MUST** be inserted into the word doc abstract body.
2. Please keep in mind that large and/or complex graphics may not be readable in print or electronic formats.
3. There should be no “white space” or border around the graphic.

4. A graphic equals 600 characters and **is not included** as part of the 2,750-character limit as long as it is included in the word doc body.

## **D. Revisions**

Revisions to your submission can be made until June 24, 2021. Please be certain to notify CCR staff if you have made and uploaded a revision so that the newest version will be used. **No changes will be accepted after June 24, 2021.** This includes adding authors to your author block or changing presenters.

## **E. Changing Presenting Authors**

If your abstract is selected for presentation, you may change the presenting author to any author listed on your abstract. Any such coauthor must also be registered as a CCR-D 21 full symposium attendee. Cancellation and registration refund of the original author's registration will be according to CCR's registration cancellation refund policies. Replacement of authors cannot be simply "substituted." You may not change the presenting author to someone who is not listed on your submission and you may not add authors after the submission deadline. If you would like for these changes to be reflected in the published version of your abstract, you must notify CCR ([pmclain@ccrheumatology.com](mailto:pmclain@ccrheumatology.com)) no later than June 24, 2021. Any presenting author must be a registered attendee, submit the abstract or upload the abstract into their registration and follow all policies and requirements of presenting authors.

## **Poster Presentation Policies - Traditional Flatboard Posters**

1. Poster presentations and faculty rounding by two thought leaders will be at 4:30pm on Thursday August 12, 2021. The posters should be up by 12 midnight CST on Wednesday August 11, 2021 and remain up until the conclusion of the poster rounding session Thursday night for attendee viewing.
2. Presenters are required to attend their boards during the 4:30pm-6pm faculty poster rounding session on Thursday. Failure to respond otherwise to the Presenters Acceptance email within 48 hours indicates your acceptance of this day/time.
3. Poster boards will be grouped together based on like subject matter. Faculty educational rounding will be scheduled during this time to encourage attendees to visit the poster sessions and interact with the presenters. Presenters with two posters in different categories may not have their posters together or one poster may not be in the correct category to allow the presenter to stand by both posters. The location of the posters within the Poster Session room is at the discretion of CCR staff.
4. Presenters must keep their posters on display for the entirety of the assigned time, as outlined in their acceptance emails. **No poster should be removed prior to 6PM on Thursday August 12, 2021** or the responsible party may forfeit any future poster submissions. Once the faculty rounding session has concluded, posters should be removed. Any posters remaining on poster boards or on the floor of the poster area will be removed and discarded if not removed by the presenter. Presenters who cannot adhere to these time requirements may choose a coauthor to present for them or remove their poster(s) at the appropriate time.
5. Presenters must post disclosures for the presenting author and lead investigator somewhere on their poster board. Failure to follow these guidelines may jeopardize

your presentation at this and future meetings.

6. Each poster board measures four feet high (121 cm) and eight feet wide (244 cm). Please make certain that the dimensions of your poster are slightly smaller than this to account for the edges of the poster board.
7. Presenters must provide the presentation material for the poster board, including all information from their abstract **and all relevant disclosure information**. Text and illustrations must be readable from distances of at least three feet away.
8. Use lightweight materials only; heavy articles are difficult to secure. Push pins will be available on site.
9. No audiovisual, projection, or computer equipment requiring electrical power will be permitted in the general poster session area.